Pharmaceuticals

Global Opioids Market Size and Forecast to 2029: Revenue, Growth, and Trends

December 3, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the opioids market from 2025–2034 with trusted insights from The Business Research Company

How Big Is The Opioids Market Size Today And What Will Its Value Be At The End Of 2029?

The adrenoleukodystrophy drugs market size has seen rapid expansion in recent years. It is forecast to increase from $0.63 billion in 2024 to $0.69 billion in 2025, with a compound annual growth rate (CAGR) of 10.1%. This historical growth can be attributed to heightened awareness of rare diseases, an uptick in orphan drug designations, governmental financial support for rare disease investigations, the advent of individualized medicine, and improvements in healthcare infrastructure.

The adrenoleukodystrophy drugs market is poised for substantial expansion in the coming years, with forecasts showing it will reach $1.03 billion by 2029, growing at a compound annual growth rate (CAGR) of 10.4%. This anticipated growth during the forecast period is primarily driven by factors such as increasing investment in rare disease research, the rising adoption of precision medicine, expanding healthcare expenditure in developing regions, advancements in newborn screening programs, and supportive regulatory environments for orphan drug development. Noteworthy trends for this period include artificial intelligence (AI)-driven drug discovery, the application of next-generation sequencing for early diagnosis, nanotechnology-based drug delivery methods, innovations in stem cell gene therapy, and strategic collaborations among biotech firms.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23293&type=smp

Which Key Drivers Are Powering Growth In The Opioids Market?

The expanding healthcare expenditure is projected to stimulate the growth of the adrenoleukodystrophy drugs market moving forward. Healthcare expenditure denotes the aggregate financial resources spent on medical services, health-related products, and associated offerings by governments, private organizations, and individuals. These expenditures are increasing due to an aging population and the rising prevalence of chronic conditions, which necessitate long-term care and continuous management, consequently leading to higher demand for healthcare services and greater outlays. Healthcare expenditure drives the demand for adrenoleukodystrophy (ALD) drugs by enhancing investments in specialized treatments for rare diseases, resulting in increased costs for research, development, and patient care. For instance, in December 2024, according to the Centers for Medicare And Medicaid Services (CMS), a US-based federal agency, national health expenditures (NHE) advanced by 7.5% in 2023, surpassing GDP growth. NHE is further anticipated to grow at 5.6% annually from 2023 to 2032. Therefore, the increasing healthcare expenditure is a key factor propelling the adrenoleukodystrophy drugs market’s growth.

Which Segment Categories Are Driving Maximum Growth In The Opioids Market?

The adrenoleukodystrophy drugs market covered in this report is segmented –

1) By Drug Class: Dietary Supplements, Antioxidants, Corticosteroids, Enzyme Replacement Therapy

2) By Indication: Childhood Cerebral Adrenoleukodystrophy, Addison’s Disease, Adrenomyeloneuropathy (AMN)

3) By Route Of Administration: Oral, Injectable, Intravenous

4) By Patient Age Group: Pediatric Patients, Adult Patients, Geriatric Patients

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Dietary Supplements: Omega-3 Fatty Acids, Vitamins, Amino Acids, Minerals

2) By Antioxidants: Vitamin E, Coenzyme Q10, Alpha-Lipoic Acid, Glutathione

3) By Corticosteroids: Prednisone, Dexamethasone, Hydrocortisone, Methylprednisolone

4) By Enzyme Replacement Therapy: Laronidase, Idursulfase, Galsulfase, Sebelipase Alfa

What Key Trends Are Driving Growth In The Opioids Market?

Major companies in the adrenoleukodystrophy (ALD) drugs market are actively seeking regulatory approvals to expand their product ranges and improve patient access to various treatment options. Regulatory approvals signify the official permission granted by government bodies, such as the FDA or EMA, which authorizes a drug or therapy for marketing and use after its safety and efficacy have been confirmed. For example, in May 2023, Minoryx Therapeutics S.L., a biotechnology company from Spain, secured FDA approval to launch a Phase 3 clinical trial (CALYX) for its key candidate, leriglitazone (MIN-102), intended for treating adult male patients with X-linked adrenoleukodystrophy (X-ALD) and cerebral adrenoleukodystrophy (cALD). This achievement represents a critical step in developing a new therapy for cALD, providing hope to individuals with few existing treatment alternatives. The trial will evaluate the drug’s safety and effectiveness in slowing or stopping the disease’s progression. Successful results could lead to its commercialization, fulfilling a crucial unmet medical need.

Who Are The Leading Companies Driving The Opioids Market?

Major companies operating in the adrenoleukodystrophy drugs market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi S.A., AstraZeneca plc, Novartis AG, Teva Pharmaceuticals USA Inc., Dr. Reddy’s Laboratories, Poxel S.A., Neuraxpharm, Mallinckrodt Pharmaceuticals plc, Nutricia, Viking Therapeutics Inc., MedDay Pharmaceuticals SAS, Voyager Therapeutics Inc., Prevail Therapeutics, Ashvattha Therapeutics, Magenta Therapeutics Inc., Minoryx Therapeutics S.L., SwanBio Therapeutics Inc., Autobahn Therapeutics Inc., bluebird bio Inc., SOM Biotech, NeuroVia.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/adrenoleukodystrophy-drugs-global-market-report

Which Region Holds The Largest Share In The Opioids Market Today?

North America was the largest region in the adrenoleukodystrophy drugs market in 2024. The regions covered in the adrenoleukodystrophy drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=23293&type=smp

Browse Through More Reports Similar to the Global Opioids Market 2025, By The Business Research Company

Anti Infective Drugs Market 2025

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market

Anti Infective Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-global-market-report

Antiobesity Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antiobesity-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795